Sexual Victimization and Disordered Eating among Sorority and Fraternity Members

A clear relationship exists between a history of sexual victimization and disordered eating behaviors characteristic of anorexia nervosa, bulimia nervosa, and binge-eating disorder. Additionally, college students and more specifically, members of Greek organizations are at an increased risk of experiencing sexual victimization and developing disordered eating behaviors. However, there is a lack of research on the effect of Greek membership on the development of different types of disordered eating behaviors following sexual assault. Additionally, research has neglected to address novel disordered eating patterns, such as those characteristic of orthorexia nervosa, and the presence of these patterns following sexual assault. To examine these concerns, 496 fulltime undergraduate students at a large, rural southeastern university were asked to complete a demographic form reporting Greek membership and rurality status, as well as several self-report measures examining experiences of sexual victimization and disordered eating behaviors. Results indicate sexual victimization was positively related to symptoms of orthorexia nervosa and symptoms of disordered eating overall (i.e., symptoms of anorexia, bulimia, and binge-eating disorder). Symptoms of orthorexia nervosa and symptoms of disordered eating were also positively related. Contrary to expectations, Greek membership was not associated with overall disordered eating behaviors and symptoms of orthorexia. Greek membership was also unrelated to sexual victimization. Furthermore, Greek membership did not moderate the relationship between sexual assault victim status and disordered eating behaviors. Finally, hometown rurality status did not moderate the relationship between sexual assault victim status and disordered eating behaviors. INDEX WORDS: Sexual victimization, Sorority, Fraternity, Disordered eating, Anorexia nervosa, Bulimia nervosa, Binge-eating disorder, Orthorexia nervosa, Rura

Mapping Atlantic coastal marshlands, Maryland, Georgia, using ERTS-1 imagery

Eastern coastal marshes are the most extensive and productive in the United States. A relatively low cost, moderately accurate method is needed to map these areas for management and protection. Groundbased and low-altitude aircraft methods for mapping are time-consuming and quite expensive. The launch of NASA's Earth Resources Technology Satellite has provided an opportunity to test the feasibility of mapping wetlands using small scale imagery. The test sites selected were in Chesapeake Bay, Maryland, and Ossabaw Island, Georgia. Results of the investigation indicate that the following may be ascertained from ERTS imagery, enlarged to 1:250,000: (1) upper wetland boundary; (2) drainage pattern in the wetland; (3) plant communities; (4) ditching activities associated with agriculture; and (5) lagooning for water-side home development. Conclusions are that ERTS will be an excellent tool for many types of coastal wetland mapping

Wetlands ecology

The author has identified the following significant results. The ERTS imagery analyzed provides approximately 2/3 coverage of the test site. Analysis was made using visual methods, density slicing, and multispectral analysis. Preliminary conclusions reached are that most, if not all, of the investigation objectives can be met. Saline and near-saline wetlands can be delineated from ERTS-1 images as the wetland-upland boundaries and land-water interface are clearly defined. Major plant species or communities such as Spartina alterniflora (high and low vigor forms), Spartina patens/Distichlis spicata, and Juncus roemarianus can be discriminated and spoil disposal areas identified

Utilizing Gene Tree Variation to Identify Candidate Effector Genes in Zymoseptoria tritici

Zymoseptoria tritici is a host-specific, necrotrophic pathogen of wheat. Infection by Z. tritici is characterized by its extended latent period, which typically lasts two weeks, and is followed by extensive host cell death and rapid proliferation of fungal biomass. This work characterizes the level of genomic variation in 13 isolates for which we have measured virulence on 11 wheat cultivars with differential resistance genes. Between the reference isolate, IPO323, and the 13 Australian isolates we identified over 800,000 single nucleotide polymorphisms, of which ~10% had an effect on the coding regions of the genome. Furthermore we identified over 1700 probable presence/absence polymorphisms in genes across the Australian isolates using de novo assembly. Finally, we developed a gene tree sorting method that quickly identifies groups of isolates within a single gene alignment whose sequence haplotypes correspond with virulence scores on a single wheat cultivar. Using this method we have identified <100 candidate effector genes whose gene sequence correlates with virulence towards a wheat cultivar carrying a major resistance gene

Photometric and spectroscopic analysis of the Type II SN 2020jfo with a short plateau

We present high-cadence photometric and spectroscopic observations of SN~2020jfo in ultraviolet and optical/near-infrared bands starting from $\sim 3$ to $\sim 434$ days after the explosion, including the earliest data with the 10.4\,m GTC. SN~2020jfo is a hydrogen-rich Type II SN with a relatively short plateau duration ($67.0 \pm 0.6$ days). When compared to other Type II supernovae (SNe) of similar or shorter plateau lengths, SN~2020jfo exhibits a fainter peak absolute $V$-band magnitude ($M_V = -16.90 \pm 0.34$ mag). SN~2020jfo shows significant H$\alpha$ absorption in the plateau phase similar to that of typical SNe~II. The emission line of stable [Ni~II] $\lambda$7378, mostly seen in low-luminosity SNe~II, is very prominent in the nebular-phase spectra of SN~2020jfo. Using the relative strengths of [Ni~II] $\lambda$7378 and [Fe~II] $\lambda$7155, we derive the Ni/Fe production (abundance) ratio of 0.08--0.10, which is $\sim 1.5$ times the solar value. The progenitor mass of SN~2020jfo from nebular-phase spectral modelling and semi-analytical modelling falls in the range of 12--15\,$M_\odot$. Furthermore, semi-analytical modelling suggests a massive H envelope in the progenitor of SN~2020jfo, which is unlikely for SNe~II having short plateaus.Comment: 20 pages (plus 5 pages appendix), 19 figures, Accepted for publication in MNRA

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Background The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19. Funding PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation